# OnCo record mtor (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/mtor/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "mtor" ;
  schema:name "mTOR"@en ;
  schema:description "mTOR is the cell's master growth controller, deciding whether to build proteins and divide. Rapamycin-like drugs clamp it down in kidney, breast and neuroendocrine cancers and in rare tumours driven by TSC gene loss."@en ;
  schema:url <https://onco.cc/targets/mtor/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/MTOR>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3942>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198793>, <https://www.uniprot.org/uniprotkb/P42345/entry>, <https://www.ncbi.nlm.nih.gov/gene/2475> ;
  schema:citation <https://www.ncbi.nlm.nih.gov/gene/2475> ;
  onco:tag "kinase" ;
  schema:alternateName "MTOR" ;
  onco:targetClass "kinase" ;
  onco:firstDescribed "1994"^^xsd:gYear ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/temsirolimus/>, <https://onco.cc/drugs/sirolimus-albumin-bound/>, <https://onco.cc/drugs/sapanisertib/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/choline-metabolism-in-cancer/>, <https://onco.cc/pathways/hepatocellular-carcinoma-signalling/>, <https://onco.cc/pathways/renal-cell-carcinoma-signalling/> .